Micro
Aftermath
Archived
Soleno Therapeutics investor sentiment
Activity declining — narrative losing relevance.
Score
0.3
Velocity
▲ 0.0
Articles
7
Sources
2
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
🤖
AI Overview
What happened: On April 6, Neurocrine Biosciences (NBIX) agreed to acquire Soleno Therapeutics (SLNO) in an all-cash deal valued at approximately $2.9 billion. Under the terms, Neurocrine will pay $53 per share, a 34% premium, representing a total equity value of $2.9 billion. The acquisition, expected to close in Q2 2023, gives Neurocrine access to Soleno's FDA-approved rare disease drug.
Market impact: The deal drove SLNO stock up 32.31% to close at $52.25, making it one of the top stocks with unexpected gains. The biotechnology sector saw increased activity, with investors eyeing potential acquisition targets. NBIX stock also saw a slight uptick, reflecting investor confidence in the deal.
What to watch next: Investors should monitor the regulatory approval process, with key catalysts including any antitrust reviews and FDA approval for the deal's closing. Additionally, watch for any updates on the integration of Soleno's rare disease drug into Neurocrine's pipeline, which could drive further stock movement.
Market impact: The deal drove SLNO stock up 32.31% to close at $52.25, making it one of the top stocks with unexpected gains. The biotechnology sector saw increased activity, with investors eyeing potential acquisition targets. NBIX stock also saw a slight uptick, reflecting investor confidence in the deal.
What to watch next: Investors should monitor the regulatory approval process, with key catalysts including any antitrust reviews and FDA approval for the deal's closing. Additionally, watch for any updates on the integration of Soleno's rare disease drug into Neurocrine's pipeline, which could drive further stock movement.
AI Overview as of Apr 09, 2026
Timeline
First SeenApr 02, 2026
Last UpdatedApr 02, 2026